Molecular-targeted anticancer drugs and immune checkpoint inhibitors (ICIs) were commonly used to improve the outcomes of patients with non-small-cell lung cancer (NSCLC) [1–5], while platinum-based chemotherapy was one key therapeutic option for NSCLC without epidermal growth factor receptor (EGFR) mutation [6–10]. Here, EGFR is linked to non-small cell lung carcinoma.